| Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients T Deuse, X Hu, A Gravina, D Wang, G Tediashvili, C De, WO Thayer, ... Nature biotechnology 37 (3), 252-258, 2019 | 600 | 2019 |
| The SIRPα–CD47 immune checkpoint in NK cells T Deuse, X Hu, S Agbor-Enoh, MK Jang, M Alawi, C Saygi, A Gravina, ... Journal of Experimental Medicine 218 (3), e20200839, 2021 | 121 | 2021 |
| De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans T Deuse, X Hu, S Agbor-Enoh, M Koch, MH Spitzer, A Gravina, M Alawi, ... Nature Biotechnology 37 (10), 1137-1144, 2019 | 98 | 2019 |
| SCNT-derived ESCs with mismatched mitochondria trigger an immune response in allogeneic hosts T Deuse, D Wang, M Stubbendorff, R Itagaki, A Grabosch, LC Greaves, ... Cell Stem Cell 16 (1), 33-38, 2015 | 76 | 2015 |
| Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques X Hu, K White, AG Olroyd, R DeJesus, AA Dominguez, WE Dowdle, ... Nature biotechnology 42 (3), 413-423, 2024 | 49 | 2024 |
| Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice X Hu, K Manner, R DeJesus, K White, C Gattis, P Ngo, C Bandoro, ... Nature Communications 14 (1), 2020, 2023 | 39 | 2023 |
| Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice X Hu, C Gattis, AG Olroyd, AM Friera, K White, C Young, R Basco, ... Science translational medicine 15 (691), eadg5794, 2023 | 35 | 2023 |
| Hypoimmune induced pluripotent stem cell–derived cell therapeutics treat cardiovascular and pulmonary diseases in immunocompetent allogeneic mice T Deuse, G Tediashvili, X Hu, A Gravina, A Tamenang, D Wang, ... Proceedings of the National Academy of Sciences 118 (28), e2022091118, 2021 | 33 | 2021 |
| Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate X Hu, K White, C Young, AG Olroyd, P Kievit, AJ Connolly, T Deuse, ... Cell Stem Cell 31 (3), 334-340. e5, 2024 | 9 | 2024 |
| A cryoinjury model to study myocardial infarction in the mouse D Wang, G Tediashvili, X Hu, A Gravina, SG Marcus, H Zhang, JE Olgin, ... JoVE (Journal of Visualized Experiments), e59958, 2019 | 9 | 2019 |
| The HY antigen in embryonic stem cells causes rejection in syngeneic female recipients X Hu, ST Kueppers, NG Kooreman, A Gravina, D Wang, G Tediashvili, ... Stem Cells and Development 29 (18), 1179-1189, 2020 | 7 | 2020 |
| Engineered hypoimmune allogeneic CAR T cells exhibit innate and adaptive immune evasion even after sensitization in humanized mice and retain potent anti-tumor activity X Hu, M Dao, K White, C Gattis, R Clarke, S Landry, R Basco, E Tham, ... Blood 138, 1690, 2021 | 6 | 2021 |
| Thalidomide treatment prevents chronic graft rejection after aortic transplantation in rats–an experimental study KK Miller, D Wang, X Hu, X Hua, T Deuse, E Neofytou, T Renne, J Velden, ... Transplant International 30 (11), 1181-1189, 2017 | 5 | 2017 |
| Abstract LB144: overexpression of CD47 protects hypoimmune CAR T cells from innate immune cell killing X Hu, M Dao, K White, R Clarke, S Landry, R Basco, C Gattis, E Tham, ... Cancer Research 81 (13_Supplement), LB144-LB144, 2021 | 4 | 2021 |
| Hypoimmune, allogeneic CD22-directed CAR T cells that evade innate and adaptive immune rejection for the treatment of large B cell lymphoma patients that are relapsed … A Johnson, H Wright, X Hu, J Kinder, N van Hoeven, O Liang, B Granger, ... Blood 142, 3437, 2023 | 2 | 2023 |
| Phase 1 study of SC291, a hypoimmune, allogeneic CD19-directed CAR T cell therapy for relapsed/refractory B-cell malignancies (ARDENT)-initial clinical data SS Neelapu, LE Budde, JP McGuirk, S Dahiya, A Deol, PA Thompson, ... Blood 142, 6852, 2023 | 2 | 2023 |
| Generation of Hypoimmunogenic Induced Pluripotent Stem Cells for Allogeneic Cell and Tissue Transplantation X Hu, T Deuse, N Kooremann, A Malik, D Wang, G Tediashvili, J Velden, ... Transplantation 101 (5S-3), S2, 2017 | 2 | 2017 |
| Development of a novel, allogeneic GPRC5D-directed CAR for treatment of multiple myeloma patients J Kinder, CA Estrada, B Granger, A O'Rourke, O Liang, A Lampano, ... Blood 142, 3290, 2023 | 1 | 2023 |
| A dual-antigen targeting, hypoimmune allogeneic CAR T to evade innate and adaptive immune rejection and overcome antigen escape A Johnson, H Wright, X Hu, B Granger, O Liang, J Moreno, M Lamba, ... Blood 140 (Supplement 1), 4552-4553, 2022 | 1 | 2022 |
| Engineered hypoimmune allogeneic CAR T cells as potential off-the-shelf CAR T cell immunotherapies X Hu, K White, C Gattis, R Clarke, S Landry, R Basco, E Tham, E Luo, ... Cancer Research 82 (12_Supplement), 5598-5598, 2022 | 1 | 2022 |
